27 results
424B8
NMRD
Nemaura Medical Inc
11 Sep 23
Prospectus unintentially filed late
4:41pm
-invasive continuous glucose monitoring. We believe the sugarBEAT® device may be readily adopted by the medical community for the assessment of a patient … .
If our product, the sugarBEAT® device, does not gain market acceptance among physicians, patients and the medical community, we will be unable
POS AM
NMRD
Nemaura Medical Inc
3 Aug 23
Prospectus update (post-effective amendment)
4:08pm
allow for non-invasive continuous glucose monitoring. We believe the sugarBEAT® device may be readily adopted by the medical community … on our business.
If our product, the sugarBEAT® device, does not gain market acceptance among physicians, patients and the medical community, we
424B4
NMRD
Nemaura Medical Inc
15 May 23
Prospectus supplement with pricing info
4:31pm
continuous glucose monitoring. We believe the sugarBEAT® device may be readily adopted by the medical community for the assessment of a patient continuously … among physicians, patients and the medical community, we will be unable to generate significant revenue, if any.
We have outsourced the bulk
CORRESP
fi1arv 84
10 May 23
Correspondence with SEC
12:00am
424B5
f548xyn
10 Apr 19
Prospectus supplement for primary offering
4:35pm
424B5
vt2nd2 ztaf7w5nigj
19 Dec 18
Prospectus supplement for primary offering
5:09pm
424B5
0b4rd
17 Dec 18
Prospectus supplement for primary offering
4:57pm
424B5
j4bwoc277
19 Oct 18
Prospectus supplement for primary offering
4:04pm